Abstract: The invention provides biomarkers that can discriminate between prostate cancer and normal tissue as well as identification of associated metastatic disease. One biomarker was identified as a peptide fragment of MEKK2. Methods of diagnosing prostate cancer, including metastatic cancer, by detecting the differential expression of one or more biomarkers are also provided.

Abstract: The present invention provides a protein-based biomarker, ApoA-II isoform, that is useful in determining prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a biological sample as prostate cancer or non-prostate cancer. The ability of ApoA-II to detect disease in patients with a normal prostate-specific antigen (PSA) makes the biomarker of this invention useful in identifying indolent disease. The biomarker can be detected by SELDI mass spectrometry, HPLC, PAGE and Western blotting.

Abstract: The present invention discloses biomarkers and biomarker combinations that have prognostic value as predictors of the developmental potential of individual IVF-derived human embryos. In particular, the biomarkers of this invention are useful to classify an embryo with implantation competence after uterine transfer or implantation incompetence. In addition, the biomarkers can be detected by non-invasive methods that do not harm the developing embryo. Also disclosed are kits for the prediction of developmental potential that detect the biomarkers of the invention, as well as methods using a plurality of classifiers to make a probable diagnosis of developmental potential.

Abstract: Disclosed are protein biomarkers and their use in diagnosing lung cancer or to make a negative diagnosis in patients. Also disclosed are kits for the diagnosis of lung cancer that detect the protein biomarkers of the invention, as well as methods using a plurality of classifiers to make a probable diagnosis of lung cancer. In certain aspects of the invention, the methods include use of a decision tree analysis. Various computer readable media and their use according to the invention are also disclosed.

Abstract: The present invention provides a protein-based biomarker, ApoA-II isoform, that is useful in determining prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a biological sample as prostate cancer or non-prostate cancer. The ability of ApoA-II to detect disease in patients with a normal prostate-specific antigen (PSA) makes the biomarker of this invention useful in identifying indolent disease. The biomarker can be detected by SELDI mass spectrometry, HPLC, PAGE and Western blotting.